These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 17506600

  • 1. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
    Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J.
    J Manag Care Pharm; 2007 May; 13(4):337-48. PubMed ID: 17506600
    [Abstract] [Full Text] [Related]

  • 2. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
    Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R.
    BMC Cancer; 2013 Jan 08; 13():11. PubMed ID: 23298389
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G, Lalla A, Barron R, Dubois RW.
    Curr Med Res Opin; 2009 Feb 08; 25(2):401-11. PubMed ID: 19192985
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J.
    Curr Med Res Opin; 2011 Jan 08; 27(1):79-86. PubMed ID: 21091127
    [Abstract] [Full Text] [Related]

  • 5. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP, Smakal M, Karanikiotis C, Wojtukiewicz MZ, Omnes Y, DeCosta L, Wetten S, O'Kelly J.
    Support Care Cancer; 2019 Apr 08; 27(4):1449-1457. PubMed ID: 30259136
    [Abstract] [Full Text] [Related]

  • 6. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z, Doan QV, Malin J, Leonard R.
    Appl Health Econ Health Policy; 2009 Apr 08; 7(3):193-205. PubMed ID: 19799473
    [Abstract] [Full Text] [Related]

  • 7. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L, Baser O, Kutikova L, Page JH, Barron R.
    Support Care Cancer; 2015 Nov 08; 23(11):3131-40. PubMed ID: 25821144
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
    De Oliveira Brandao C, Lewis S, Sandschafer D, Crawford J.
    Curr Med Res Opin; 2023 May 08; 39(5):707-718. PubMed ID: 36976784
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
    Almenar D, Mayans J, Juan O, Bueno JM, Lopez JI, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J.
    Eur J Cancer Care (Engl); 2009 May 08; 18(3):280-6. PubMed ID: 19076208
    [Abstract] [Full Text] [Related]

  • 13. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
    Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S.
    Support Care Cancer; 2022 Jul 08; 30(7):6327-6338. PubMed ID: 35482126
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
    Mahtani R, Crawford J, Flannery SM, Lawrence T, Schenfeld J, Gawade PL.
    BMC Cancer; 2021 May 27; 21(1):621. PubMed ID: 34044798
    [Abstract] [Full Text] [Related]

  • 16. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
    Donkor KN, Selim JH, Waworuntu A, Lewis K.
    Ann Pharmacother; 2017 Oct 27; 51(10):840-847. PubMed ID: 28597691
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.
    Danova M, Chiroli S, Rosti G, Doan QV.
    Tumori; 2009 Oct 27; 95(2):219-26. PubMed ID: 19579869
    [Abstract] [Full Text] [Related]

  • 20. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M, Esteves S, André R, Isidoro M, Moreira A.
    Support Care Cancer; 2016 Feb 27; 24(2):597-603. PubMed ID: 26111956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.